

Changes to legislation: There are currently no known outstanding effects for the
Commission Regulation (EU) No 1228/2014, ANNEX II. (See end of Document for details)

ANNEX II

Rejected health claims

Application — Relevant provisions of Regulation (EC) No 1924/2006	Nutrient, substance, food or food category	Claim	EFSA opinion reference
Article 14(1)(a) health claim referring to a reduction of a disease risk	Glucosamine hydrochloride	Slowing down/ reduce the destruction process of cartilage of the musculoskeletal system and consequently reduce the risk of osteoarthritis.	Q-2009-00412
Article 14(1)(a) health claim referring to a reduction of a disease risk	Isolated soy protein	Protein-rich soybean component has been shown to lower/reduce blood cholesterol; blood cholesterol lowering may reduce the risk of (coronary) heart disease.	Q-2011-00784
Article 14(1)(a) health claim referring to a reduction of a disease risk	Plant sterols in combination with Cholesternorm®mix	Actively lowers cholesterol.	Q-2009-00237 Q-2011-01114
Article 14(1)(a) health claim referring to a reduction of a disease risk	Eicosapentanoic acid (EPA)	EPA has been shown to reduce the AA/ EPA ratio in blood. A high AA/EPA level is a risk factor in the development of attention difficulties in children with ADHD-like symptoms. These children are also characterised by less hyperactivity and/or coexisting oppositional behaviour.	Q-2012-00573
Article 14(1)(a) health claim referring	Plant stanols (as plant stanol esters)	Consuming 2 g/day plant stanols (as plant stanol esters)	Q-2012-00915

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EU) No 1228/2014, ANNEX II. (See end of Document for details)

to a reduction of a
disease risk

as part of a diet
low in saturated fat
results in a 2-fold
greater reduction
in LDL-cholesterol
than consuming a
low saturated fat
diet alone. High
cholesterol is a
risk factor in the
development of
coronary heart
disease.

Changes to legislation:

There are currently no known outstanding effects for the Commission Regulation (EU) No 1228/2014, ANNEX II.